Janumet (Sitagliptin Phos/Metformin HCl) Patent Expiration, LOE Window & CMS Spending

Janumet (Sitagliptin Phos/Metformin HCl) by Merck & Co.: FDA Orange Book core substance LOE 2027-05-24 (last listed 2029-01-21), 2 AB generics, $846.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN022044 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-05-24
Last Listed Patent or Exclusivity Date2029-01-21
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$846.7M
2024 Medicare Part D Spend$709.2M
2024 Medicaid Spend$137.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.